 CAMBRIDGE, Mass., July 27, 2022 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financial results and operational highlights in a conference call on August 4, 2022, at 8 a.m. ET. 